Nuclear factor-κ13 in development, prevention, and therapy of cancer

被引:255
作者
Van Waes, Carter
机构
[1] Natl Inst Deafness & Other Commun Disorders, Head & Neck Surg Branch, Bethesda, MD 20892 USA
[2] NCI, Ctr Canc Res, Bethesda, MD 20892 USA
关键词
D O I
10.1158/1078-0432.CCR-06-2221
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Nuclear factor-kappa B (NF-kappa B) is a signal transcription factor that has emerged as an important modulator of altered gene programs and malignant phenotype in development of cancer. Major carcinogens and oncogenic viruses induce NF-kappa B activation, and a variety of subsequent oncogenic events contribute to a progressive increase in constitutive NF-kappa B activation as an important common pathway in most forms of cancer. NF-kappa B target genes promote tumor cell proliferation, survival, migration, inflammation, and angiogenesis. Inhibition of NF-kappa B has been found to be an important mechanism of action of steroids, nonsteroidal anti-inflammatory drugs, and natural and synthetic compounds that show therapeutic and preventive activity. Newer agents targeting the proteasome, inhibitor-kappa B kinase, and other upstream kinases involved in NF-kappa B activation have shown anticancer activity in clinical or preclinical studies.
引用
收藏
页码:1076 / 1082
页数:7
相关论文
共 100 条
[41]   Links between α-catenin, NF-κB, and squamous cell carcinoma in skin [J].
Kobielak, A ;
Fuchs, E .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2006, 103 (07) :2322-2327
[42]  
Kojima M, 2004, ANTICANCER RES, V24, P675
[43]   Phase II trial of bortezomib for patients with advanced renal cell carcinoma [J].
Kondagunta, GV ;
Drucker, B ;
Schwartz, L ;
Bacik, J ;
Marion, S ;
Russo, P ;
Mazumdar, M ;
Motzer, RJ .
JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (18) :3720-3725
[44]  
Lam LT, 2005, CLIN CANCER RES, V11, P28
[45]   Nuclear factor-κB is an important modulator of the altered gene expression profile and malignant phenotype in squamous cell carcinoma [J].
Loercher, A ;
Lee, TL ;
Ricker, JL ;
Howard, A ;
Geoghegen, J ;
Chen, Z ;
Sunwoo, JB ;
Sitcheran, R ;
Chuang, EY ;
Mitchell, JB ;
Baldwin, AS ;
Van Waes, C .
CANCER RESEARCH, 2004, 64 (18) :6511-6523
[46]  
LOERCHER A, 2004, CANCER RES, V64, P8130
[47]   Inhibition of NF-κB in cancer cells converts inflammation-induced tumor growth mediated by TNFα to TRAIL-mediated tumor regression [J].
Luo, JL ;
Maeda, S ;
Hsu, LC ;
Yagita, H ;
Karin, M .
CANCER CELL, 2004, 6 (03) :297-305
[48]   IKK/NF-κB signaling: balancing life and death -: a new approach to cancer therapy [J].
Luo, JL ;
Kamata, H ;
Karin, M .
JOURNAL OF CLINICAL INVESTIGATION, 2005, 115 (10) :2625-2632
[49]   A phase I and pharmacologic study of sequences of the proteasome inhibitor, bortezomib (PS-341, Velcade™), in combination with paclitaxel and carboplatin in patients with advanced malignancies [J].
Ma, Cynthia ;
Mandrekar, Sumithra J. ;
Alberts, Steven R. ;
Croghan, Gary A. ;
Jatoi, Aminah ;
Reid, Joel M. ;
Hanson, Lorelei J. ;
Bruzek, Laura ;
Tan, Angelina D. ;
Pitot, Henry C. ;
Erlichman, Charles ;
Wright, John J. ;
Adjei, Alex A. .
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2007, 59 (02) :207-215
[50]   A phase II trial with pharmacodynamic endpoints of the proteasome inhibitor bortezomib in patients with metastatic colorectal cancer [J].
Mackay, H ;
Hedley, D ;
Major, P ;
Townsley, C ;
Mackenzie, M ;
Vincent, M ;
Degendorfer, P ;
Tsao, MS ;
Nicklee, T ;
Birle, D ;
Wright, J ;
Siu, L ;
Moore, M ;
Oza, A .
CLINICAL CANCER RESEARCH, 2005, 11 (15) :5526-5533